Multiple South West London Pathology Trusts Select Indica Labs and Leica Biosystems for Advancing Digital Pathology in Clinical Practice

Multiple NHS trusts within South West London Pathology chose HALO AP® and Leica Biosystems Aperio GT 450 DX for their digital pathology solutions.

With 45 pathologists and over half a million whole slide images (WSIs) produced annually, this network of London trusts deploys Aperio GT 450 DX scanners and HALO AP® to support diagnostic collaboration across multiple locations
Cloud-based technology will be employed to manage and store large data files produced by WSI
The team at Indica Labs is integrating multiple LIMS into one unified digital pathology platform, HALO AP®, for a cohesive clinical workflow and to facilitate sharing and collaboration across South West London Pathology.

Albuquerque, NM, September 24, 2025 – Indica Labs, the global leader of AI-powered digital pathology, and Leica Biosystems, a global leader in anatomic and digital pathology solutions, announce today that multiple trusts within the South West London Pathology network have chosen the powerful combination of Leica Biosystems Aperio GT 450 DX scanners and Indica Labs’ HALO AP® for digital pathology adoption. This combined solution will be leveraged to facilitate remote working and cross-site collaboration; improve case turnaround time; and prepare for future integration of AI-based image analysis for enhanced diagnostic accuracy and speed. The initial aims are to digitize workflows and achieve 100% glass slide scanning and 60% digital reporting in Cellular Pathology, shortly after deployment, with a view to onboard other subspecialties within 3-6 months.

This digital pathology project is part of a broader national initiative by NHS England and the National Cancer Improvement Turnaround Programme aimed at improving cancer diagnostic turnaround times and producing more accurate test results, while providing a centralized cloud-based deployment to facilitate collaboration across multiple hospitals and NHS trusts. Funding is provided by the Cancer Programme under the Diagnostics Digital Capability Programme.

This network of trusts will lead the field of digital pathology with their centralized cloud-based deployment for data management and WSI storage. The network includes 45 pathologists across several subspecialities, and they produce over half a million slides each year. With the large volume of annual pathology cases and many working pathologists spread across multiple sites, a cutting-edge digital pathology solution with a cloud-based centralized deployment enables seamless collaboration across institutions. This environment also future-proofs each laboratory, ensuring scalable data management and multiple options for bringing in AI-powered diagnostics.

“We are thrilled to be part of this national programme and local initiative and to be creating a harmonized network for digital pathology across south west London,” noted Simon Brewer, Managing Director of South West London Pathology. “The potential benefits to our patients in terms of higher productivity and improved turnaround times are significant. Our ability to more easily collaborate on cases will greatly improve the flow of information across sites and will mean that we can report on complex cases without the need to transport precious samples, removing the risk of samples being lost or damaged. It is exciting to be at the cutting edge of digital pathology in the UK and leading the way for other NHS trusts and organizations through our partnership with Indica Labs and Leica Biosystems.”

Throughout the ongoing integration process, the team at Indica Labs showcased their technical and operational ability by integrating multiple Laboratory Information Management Systems (LIMS) into one unified digital pathology platform: a complex technological challenge, requiring highly trained experts. Each LIMS has a different architecture, data models and workflows that need intricate configuration to ensure real-time communication between systems. LIMS integration is imperative in the digital pathology implementation process and will provide consistency and efficiency to enable the highest quality of patient care across South West London Pathology.

"We’re excited to be an integral part of the trusts’ transition to digital pathology for more reliable and efficient diagnostics,” said Steven Hashagen, CEO of Indica Labs. “In partnership with Leica Biosystems, our teams are well positioned to support improved patient care through the implementation of integrated digital pathology across southwest London hospitals."

"Leica Biosystems is proud to partner with Indica Labs and various NHS trusts to help drive the next chapter of digital pathology within the NHS,” said Naveen Chandra, Vice President of Digital Pathology at Leica Biosystems. “By combining our high-throughput Aperio GT 450 DX scanners with HALO AP®, we are delivering an integrated solution that enables faster diagnoses, more streamlined workflows, and stronger cross-site collaboration. This initiative represents a significant step toward scalable, AI-enabled pathology services that directly support better patient care."

HALO AP® is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland. HALO AP® is For Research Use Only in the USA and is not FDA cleared for clinical diagnostic use. In addition, HALO AP® provides built-in compliance with FDA 21 CFR Part 11, HIPAA, and GDPR. PRR-MAR-000001v1

About Indica Labs

Indica Labs is the global leader in AI-powered digital pathology software and services. Our flagship HALO® and HALO AI platform revolutionizes quantitative evaluation of whole slide images. HALO Link provides collaborative image management while HALO AP® and HALO AP Dx deliver enterprise digital pathology for primary diagnosis with regulatory clearances in multiple markets. Through a commitment to open pathology, performance, scalability, and ease-of-use, we help pharma companies, diagnostic labs, hospitals, research organizations, and Indica’s own Cloud and Pharma Services make discoveries and diagnoses that transform patient care and scientific discovery.

About Leica Biosystems

Leica Biosystems is a cancer diagnostics company and a global leader in anatomic and digital pathology solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step. The company’s mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of its corporate culture. Leica Biosystems is proud to be a Danaher Corporation subsidiary.

Indica Labs Media Contact: Adam Smith

Leica Biosystems Media Contact: Emma Brown